Skip to content

Study of Nesiritide in Diastolic Heart Failure.

A Study of the Acute Hemodynamic and Myocardial Effects of Nesiritide in Diastolic Heart Failure.

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00309868
Enrollment
20
Registered
2006-04-03
Start date
2002-12-31
Completion date
2003-12-31
Last updated
2014-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diastolic Heart Failure

Keywords

heart catheterization, echocardiogram, nesiritide

Brief summary

We hypothesize that nesiritide will have favorable effect in decreasing heart filling pressures and echocardiogram studies.

Detailed description

In previous studies, patients with systolic heart failure were given nesiritide and had reduced heart filling pressures. The FDA has approved nesiritide for these patients. Between one-third and one-half of patients with heart failure have diastolic heart failure. Few of these patients have been studied while receiving nesiritide. A study is needed to test nesiritide on this specific type of heart failure. Patients will undergo a heart catheterization and heart biopsy. Patients will then be transferred to the intensive care unit for monitoring. An echocardiogram will be obtained, followed by an infusion of nesiritide for 24 hours. At the completion of the infusion, a repeat echocardiogram will be obtained.

Interventions

Sponsors

Scios, Inc.
CollaboratorINDUSTRY
Massachusetts General Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Elevated heart filling pressure. Ejection fraction \>45%. Blood pressure \>90. Physician feels that the patient needs intravenous medication for heart failure. \-

Exclusion criteria

Patients receiving intravenous medication. Patients with significant heart disease or who are unstable. Patients with kidney failure or severe heart valve disease. \-

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026